<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[RSS Feed]]></title><description><![CDATA[RSS Feed]]></description><link>http://direct.ecency.com</link><image><url>http://direct.ecency.com/logo512.png</url><title>RSS Feed</title><link>http://direct.ecency.com</link></image><generator>RSS for Node</generator><lastBuildDate>Mon, 11 May 2026 22:44:49 GMT</lastBuildDate><atom:link href="http://direct.ecency.com/created/sanofipasteur/rss.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Dengvaxia Cases Moving Forward - Charges For Sanofi Philippine Employees But Why Not For Executive Board?]]></title><description><![CDATA[The forced vaccination of hundreds of thousands of Philippine children with Dengvaxia was halted after the children started dying. I have been covering this unfolding case as it has developed and now we]]></description><link>http://direct.ecency.com/vaccines/@jockey/dengvaxia-cases-moving-forward-charges-for-sanofi-philippine-employees-but-why-not-for-head-office-in-switzerland</link><guid isPermaLink="true">http://direct.ecency.com/vaccines/@jockey/dengvaxia-cases-moving-forward-charges-for-sanofi-philippine-employees-but-why-not-for-head-office-in-switzerland</guid><category><![CDATA[vaccines]]></category><dc:creator><![CDATA[jockey]]></dc:creator><pubDate>Wed, 26 Jun 2019 09:24:51 GMT</pubDate><enclosure url="https://images.ecency.com/p/6KincH1mMRDELmKnnjdU4UHt2fC2WfFZBpGeMyg4QTCSizmZKew6wCQohsjBUGbE1AtPQ9fFSJhrHxFBwdTQFhZEoekcEewu8YV6bW3rGuju8y9y8UtGx7wY5WLQZfxj2thqJj1d3drjLRrMLt7SvCj45rKCLpYpeYhH5aQAW6c2AF1w3pcXmG?format=match&amp;mode=fit" length="0" type="false"/></item><item><title><![CDATA[Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Growth Rate Segment Forecast 2018]]></title><description><![CDATA[A fresh report has been added to the wide database of Market Research Hub (MRH) titled “Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Research Report (2018-2025)” which provides an outlook]]></description><link>http://direct.ecency.com/pharmaceutical/@johnpark49/global-23-valent-pneumococcal-polysaccharide-vaccine-market-growth-rate-segment-forecast-2018</link><guid isPermaLink="true">http://direct.ecency.com/pharmaceutical/@johnpark49/global-23-valent-pneumococcal-polysaccharide-vaccine-market-growth-rate-segment-forecast-2018</guid><category><![CDATA[pharmaceutical]]></category><dc:creator><![CDATA[johnpark49]]></dc:creator><pubDate>Mon, 12 Mar 2018 12:13:54 GMT</pubDate></item></channel></rss>